Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
Abstract Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate healthy from malignant cells limits the efficacy of immunotherapeutic approaches. The T cell receptor expresses one of two highly ho...
| Published in: | Nature Communications |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Online Access: | https://doi.org/10.1038/s41467-024-45854-3 |
